Connor, Clark & Lunn Investment Management Ltd. Halozyme Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$37.81 - $52.4 $1.4 Million - $1.94 Million	37,082 New	37,082 $1.94 Million
Q4 2023 Feb 09, 2024	SELL	$33.32 - $42.1 $462,015 - $583,758	-13,866 Reduced 8.01%	159,242 $5.89 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $2.28 Million - $2.76 Million	62,628 Added 56.69%	173,108 $6.61 Million
Q2 2023 Aug 10, 2023	SELL	$30.28 - $38.74 $688,203 - $880,482	-22,728 Reduced 17.06%	110,480 $3.99 Million
Q1 2023 May 09, 2023	BUY	$32.86 - $55.7 $909,203 - $1.54 Million	27,669 Added 26.22%	133,208 $5.09 Million
Q4 2022 Feb 10, 2023	BUY	$40.06 - $59.44 $4.23 Million - $6.27 Million	105,539 New	105,539 $6.01 Million
Q2 2022 Aug 05, 2022	BUY	$37.35 - $48.3 $1.4 Million - $1.81 Million	37,513 New	37,513 $1.65 Million
Q1 2021 May 13, 2021	SELL	$39.51 - $51.45 $210,667 - $274,331	-5,332 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $137,618 - $232,581	5,332 New	5,332 $228,000
Q3 2017 Nov 14, 2017	SELL	$11.76 - $17.4 $136,710 - $202,274	-11,625 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	11,625	11,625 $149,000

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$838 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$613 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$315 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$193 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$162 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account